Aclaris Therapeutics Stock (NASDAQ: ACRS)

Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Medicine,Development,Laboratory:,Caucasian,Female,Scientist,Using,Microscope,,Analyzes,Petri

News

Upgrades

Price Target

Analyst Ratings

Trading Ideas

ACRS

HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and asthma.

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Analysts

Markets

GCMG

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

Analyst Color

Biotech

Health Care

Contracts

Movers

General

Aclaris secures global rights to Biosion&#39;s BSI-045B, advancing trials for atopic dermatitis, asthma, and more. Stock surges on promising updates.

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics Inc

Press Releases

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

This Healthcare Stock is Soaring Following Exclusive License Agreement Announcement

Peraso Inc. (NASDAQ: PRSO): Intro-Act Targets $3.30 Per Share After Positive Q3 Performance see more stocks inside….

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Earnings

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

ALCE

PRSO

QUBT

TRNR

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Biote

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

MBX Biosciences

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Cassava Sciences

scPharmaceuticals

Septerna

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Ventyx Biosciences

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

Aclaris Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga